SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Direxion Shares ETF Trust - Direxion Daily Junior Gold Miners Index Bull 2X ETF

Direxion Daily Junior Gold Miners Index Bull 2X Shares

JNUG is trending as investors capitalize on surging gold prices and heightened market volatility, with the community actively debating whether the current price action signals a sustainable long-term breakout or an overextended blow-off top. The conversation is dominated by contrasting views on whether to continue riding the momentum in mining ETFs or prepare for a significant pullback as broader macro concerns like deficit spending and central bank policies remain central to the bullish sentiment.

Hyperliquid is a performant L1 optimized from the ground up. The vision is a fully onchain open financial system with user built applications interfacing with performant native components, all without compromising end user experience.   The Hyperliquid L1 is performant enough to operate an entire ecosystem of permissionless financial applications – every order, cancel, trade, and liquidation happens transparently on-chain with block latency &lt;1 second. The chain currently supports 100k orders / second.  The Hyperliquid L1 uses a custom consensus algorithm called HyperBFT which is heavily inspired by Hotstuff and its successors. Both the algorithm and networking stack are optimized from the ground up to support the L1.   The flagship native application is a fully onchain order book perpetuals exchange, the Hyperliquid DEX. Further developments include a native token standard, spot trading, permissionless liquidity, etc.

Hype

Hyperliquid ($HYPE) is capturing significant attention as traders debate its long-term utility versus competitors like Aster and Avantis, while community discussions remain split between those bullish on its deflationary tokenomics and others wary of upcoming token unlocks. The conversation is heavily focused on HYPEs role as a dominant decentralized perpetual exchange, with investors closely watching its institutional volume growth and the potential for a broader market rotation into perp-DEX platforms.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is facing intense community polarization, with persistent criticism regarding its long-term price performance and leadership transparency contrasting against a dedicated base of "diamond-handed" investors who view current price levels as a strategic accumulation opportunity. While detractors highlight comparisons to other trending tokens and label the project a scam due to the lack of immediate price action, supporters continue to anchor their thesis on institutional developments like the Coinbase 50 inclusion and the belief that the project's utility and regulatory compliance will drive value in the coming years.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is facing significant market volatility as investors weigh the mixed interim Phase 2 results for its inhaled mRNA cystic fibrosis therapy, ARCT-032. While the company reported positive signals in mucus reduction and confirmed the treatment was generally safe and well-tolerated, the community is actively debating whether these early indicators justify the sharp decline or if the stock is currently oversold given its cash position and broader rare disease pipeline.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Delta Air Lines is catching investor attention as analysts highlight the sector's resilience and robust holiday demand projections despite persistent headwinds from fuel volatility and operational disruptions. The community is actively debating the stock's long-term value against recurring macro-shocks, with heavy options activity signaling heightened interest in potential price momentum heading into the new year.

Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.

Inventiva - ADR

Inventiva is attracting investor attention following the initiation of coverage by several analysts with buy ratings, fueling discussions about the potential of its lead asset, lanifibranor, in the MASH market. Community members are actively debating the company's valuation gap compared to sector peers and its long-term prospects as a potential acquisition target for larger pharmaceutical firms.

Golar LNG Ltd. owns and operates liquefied natural gas carriers, floating storage, and regasification unit. It operates through the following segments: Vessel Operations, FLNG, and Power. The Vessel Operations segment operates and charter out vessels on fixed terms to customers. The FLNG segment provides integrated upstream and midstream solution for the development of gas reserves to LNG. The Power segment integrated LNG based downstream solutions, through the ownership and operation of FSRUs and associated terminal and power generation infrastructure. The company was founded on May 10, 2001 and is headquartered in Hamilton, Bermuda.

Golar Lng

Golar LNG is trending as investors bet on the company's critical role in the global energy supply chain, specifically through its floating liquefaction infrastructure amid ongoing geopolitical tensions and tight supply constraints. Market participants are actively discussing the stock's potential to capitalize on long-term project backlogs and the broader structural shift toward mobile, reliable energy export solutions.

Cenovus Energy, Inc. is a Canadian-based integrated energy company, which engages in the provision of gas and oil. It operates through the following segments: Upstream, Downstream, and Corporate and Eliminations. The Upstream segment refers to operations of oil sands, conventional, and offshore. The Downstream segment operates the Canadian and U.S. refining. The Corporate and Eliminations segment includes the corporates costs for general and administrative. The company was founded in 1881 and is headquartered in Calgary, Canada.

Cenovus Energy Inc

Cenovus Energy is trending as investors weigh strong production growth and operational efficiency against geopolitical uncertainties that are tightening global oil supply. The community is actively debating the company's valuation, recent share buyback activity, and the long-term strategic benefits of expanding pipeline capacity to reach new export markets.

United States Commodity Funds LLC - United States 12 Month Natural Gas Fund

United States 12 Month Natural Gas

UNL is drawing increased attention as investors weigh the complexities of long-term natural gas exposure, specifically focusing on the fund's 12-month rolling contract strategy compared to more volatile, front-month focused alternatives like UNG and BOIL. Community discussions highlight ongoing debate over the impact of storage levels, seasonal demand cycles, and geopolitical risks, with many participants using UNL as a lower-decay vehicle for navigating the sector's characteristic price swings and contango-related challenges.

Boyd Gaming Corp. is a multi-jurisdictional gaming company, which engages in the management and operation of gaming and entertainment properties. It operates through the following segments: Las Vegas Locals, Downtown Las Vegas, Midwest and South, and Online. The Las Vegas Locals segment consists of eight casinos that primarily serve the resident population in the Las Vegas metropolitan area. The Downtown Las Vegas segment refers to the following casinos: California Hotel and Casino, Fremont Hotel and Casino, and Main Street Station Hotel and Casino. The Midwest and South segment includes four land-based casinos, six dockside riverboat casinos, three racinos, and four barge-based casinos that operate in nine states in the Midwest and southern United States. The Online segment includes the operating results of online gaming operations. The company was founded by William Samuel Boyd and Sam Boyd on January 1, 1975 and is headquartered in Las Vegas, NV.

Boyd Gaming Corp.

Boyd Gaming is trending as traders speculate on potential M&A activity following reports that the company has approached Penn Entertainment regarding a possible acquisition, while community members actively debate the differences between this regional casino operator and the Chinese EV manufacturer. Investors are closely monitoring these consolidation rumors, particularly the potential for a split of brick-and-mortar assets and digital gaming divisions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

When Wall Street Rotates, Biotech Innovators Emerge: The Untapped Opportunities in Oncology

Market rotations are as old as Wall Street itself. When capital exits overheated sectors like big tech, it often finds its way into undervalued industries ripe for rediscovery. The latest shift, away from pricey artificial intelligence and semiconductor stocks, has once again turned investors&#8217; attention toward biotechnology. And within biotech, the most compelling breakthroughs are not in computing or automation, but in humanity&#8217;s longest-standing battle: defeating cancer.As institutional money seeks new opportunities, healthcare and biotech have emerged as natural ...

Propanc Biopharma tumbled 17% in after-hours trading on Monday, with activity surging to nearly 33,000 times its usual volume, aligning with the volatile trend the stock has been witnessing since the cancer drug developer completed its move from the OTC Pink market to the Nasdaq Capital Market and announced a $4 million share sale.Propanc tumbled nearly 20% in premarket trading Tuesday, after more than doubling on Monday in its best session in four months with a 103.8% gain to $5.85.The company said on Aug. 14 it had secured approval to uplist, with trading on Nasdaq starting Aug. 15 under the same “PPCB” ticker. Its shares were last quoted on the OTC Pink at the close of business Aug. 14.On Thursday, Propanc priced the one million shares at $4 each, targeting $4 million in gross proceeds before costs, and gave underwriters a 45-day option to buy another 150,000 shares.&nbsp;The deal is expected to close on Aug. 18, led by D. Boral Capital and Craft Capital Management.&nbsp;A registration statement for the offering was declared effective by the SEC on Aug. 13.The Melbourne-based biotech said it plans to use the cash for working capital and general expenses.&nbsp;Propanc is developing a proenzyme therapy designed to block the spread and recurrence of solid tumors such as pancreatic, ovarian and colorectal cancers by attacking cancer stem cells.On Stocktwits, retail sentiment for Propanc was ‘extremely bullish’ amid ‘extremely high’ message volume, making it one of the most trending equities on the platform.&nbsp;One user noted that Propanc was looking strong with volume picking up and the chart setting up for what could be the start of a big run.&nbsp;<stembedurl>https://stocktwits.com/Elena11898/message/625706251</stembedurl>Another user remarked that it was lucky no funds chased the stock that day, adding that a drop under $2 might come tomorrow.<stembedurl>https://stocktwits.com/letuan7/message/625718778</stembedurl><a href="https://stocktwits.com/symbol/PPCB">Propanc’s stock</a> has declined 51.2% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Propanc Biopharma (PPCB) tumbled 17% in after-hours trading on Monday, with activity surging to nearly 33,000 times its usual volume. (Photo credit: Getty Images)

Why Propanc stock Is Tumbling In Premarket Today

The biotech firm announced a $4 million share sale alongside its Nasdaq uplisting, sending trading volumes surging to record levels. 

Equity

This account has been verified as an official PPCB representative.

Verified Account

IR Propanc Bio

Propanc Biopharma, Inc. is a development-stage healthcare company, which engages in the research and development of cancer treatments. The firm focuses on the treatment of pancreatic, ovarian, and colorectal cancer. It offers its product pipeline, including PRP and POP1. The company was founded by James Nathanielsz and Julian Kenyon on October 15, 2007 and is headquartered in Camberwell, Australia.

PPCB
Propanc Biopharma Inc

Feed

News

Sentiment

Fundamentals

Info

Latest PPCB News

PPCBPropanc Biopharma Inc